Personalized Neoantigen Mrna Tumor Vaccine
Esophageal Squamous Cell Carcinoma
Explore 64 assets in Esophageal Squamous Cell Carcinoma →Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Changhai Hospital
Modality
vaccine
Development Phase
N/A
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03468244CT.gov Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Digestive System Neoplasms | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Esophageal Squamous Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Personalized Neoantigen Mrna Tumor Vaccine (this asset) | Changhai Hospital | N/A | D · 30 |
| Fluorouracilum | AstraZeneca | P3 | B |
| Oxaliplatin | Taiho Oncology, Inc. | P3 | B |
| Pembrolizumab | GV20 Therapeutics | P3 | B |
| Levofolinic Acid | Taiho Oncology, Inc. | P3 | B |
| Cetuximab | Hummingbird Bioscience | P2 | B |
| Cis-Diamminedichloroplatinum Ii | AstraZeneca | P3 | B |
| Irinotecan | Taiho Oncology, Inc. | P2 | B |
| Capecitabine | Chongqing University Cancer Hospital | P2 | B |
+42 more in the Esophageal Squamous Cell Carcinoma cohort
Other indications for Personalized Neoantigen Mrna Tumor Vaccine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hepatocellular Carcinoma | — | N/A | D · 30 |
| Gastric Adenocarcinoma | — | N/A | D · 30 |
| Pancreatic Adenocarcinoma | — | N/A | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Personalized Neoantigen Mrna Tumor Vaccine in Esophageal Squamous Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/personalized-neoantigen-mrna-tumor-vaccine-esophageal-squamous-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →